

routinely recommended for pregnant women in the UK despite adverse effects on pregnancy, neonate and mother. Countries with recommended CT screening in pregnancy have good results despite suboptimal uptake.

Aim(s) To determine the prevalence of CT and treatment uptake in pregnant and non-pregnant women who have attended a large, busy urban integrated sexual health service.

Methods Retrospective observational cohort study of all patient encounters with women of child bearing age (15 to 49) between 2012 and 2015 who were tested for CT. Women with a positive pregnancy and STI testing 2 weeks prior and 9 months post STI test were included ($n = 837$). Women with terminations were excluded. Socio-demographic factors and clinical factors were compared to 20,629 women who had a CT test but no pregnancy.

Results: Pregnant women were on average younger (25 vs 28) and had higher CT prevalence across all age groups (12 vs 5%), peaking between 15 and 25 years (21 vs 10%). Being pregnant doubled the odds of having CT after controlling for age (adjusted OR 1.96; CI 1.64–2.30).

Discussion The national opportunistic screening programme is deemed to cover CT detection in an age group where both STIs and pregnancy rates are high. However, the results of our study support additional targeted CT screening during pregnancy, particularly in the youngest age group.

P211 BASHH ON TWITTER: SOCIAL MEDIA FOR SEXUAL HEALTH

¹Adele Wolujewicz*, ¹Mark Lawton, ²Nick Theobald, ¹Martyn Wood. ¹Royal Liverpool University Hospital, Liverpool, UK; ²BASHH, Macclesfield, UK

10.1136/sextrans-2016-052718.259

Background/introduction Twitter is a free, online social networking service through which users can read and send brief messages of up to 140-characters called “Tweets.” BASHH (@BASHH-UK) currently has 3479 followers on Twitter. These include professionals working in sexual health, sexual health services with their own Twitter accounts and members of the public. Twitter disseminates messages instantly and can influence a wide audience. It can be used to keep health professionals and patients informed about relevant research and headline news. For example, recent Twitter themes have included discussions about PrEP and gonorrhoea resistance. Twitter is also used for sharing practical information such as conference deadlines.

Aim(s)/objectives To evaluate the reach of BASHH on Twitter by reporting BASHH’s Twitter activity.

Methods Using Twitter Analytics, data was obtained on the number of Tweets and Tweet Impressions for each of the last 4 months. Tweet Impressions are counted as the number of times each Tweet is seen. The number of visits to BASHH’s Twitter profile, mentions by other Twitter users and number of new followers are also recorded. This is presented below:

Results

Abstract P211 Table 1 BASHH on Twitter

Month	Tweets	Tweet Impressions	Profile Visits	Mentions	New followers
November 2015	18	19200	1122	105	120
December 2015	31	36600	1548	83	67
January 2016	49	45500	2398	222	120
February 2016	33	28100	2394	125	108

Discussion/conclusion BASHH’s Twitter activity is reaching a large audience and increasing. All individuals working in sexual health and HIV should consider using Twitter to support wider engagement with their professional network.

P212 WHICH PATIENTS MAY BE ELIGIBLE FOR PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV?

Helen Bradshaw, Laura Cunningham, Rachel Drayton, Nicola Lomax*. Cardiff and Vale University Healthboard, Cardiff, UK

10.1136/sextrans-2016-052718.260

Background/introduction HIV diagnoses remain high among men who have sex with men (MSM). Recent studies show promising results with reducing MSM HIV transmission. The PROUD and IPERGAY studies, using daily or ‘on demand’ Truvada as PrEP respectively, showed an 86% HIV transmission reduction. Clinical guidance and funding arrangements for PrEP are in development. We assessed PrEP eligibility amongst MSM attending our sexual health service.

Aim(s)/objectives To ascertain the proportion of MSM attending our service eligible for PrEP on clinical grounds and estimate the service and cost implications of introducing PrEP.

Methods 97 MSM attending from December 2014 to July 2015 were reviewed, including patients who had attended for post-exposure prophylaxis and STI screening. Patients were assessed against the PROUD study inclusion criteria to identify those who would benefit from PrEP.

Results

Abstract P212 Table 1 Eligible for PrEP

Inclusion criteria	Percentage of patients who fit the criteria
Born male	100%
Completed HIV and STI screen	84%
HIV negative within previous 4 weeks	95%
Unprotected anal intercourse (UPAI) on > one occasion in the previous 90 days	16%
All criteria fulfilled (Having attended at least once previously was not considered as this was felt unnecessary)	14%

No patients met any of the PROUD exclusion criteria. In a further 21% of notes, the exact number of episodes of UPAI, if any, was unclear although all other criteria were met. This suggests a range of 14–35% eligible for PrEP. We assumed all patients would continue having UPAI, were willing to comply with additional visits and were able to provide consent. The annual cost of Truvada is £356 per year. Further service cost analyses will be described.

Discussion/conclusion At least 14–35% of MSM attending our service may benefit from PrEP provision. Additional costs include STI screening, monitoring and care pathways will need to be introduced. However, the overall impact of PrEP may be to reduce new HIV diagnoses and the resultant care costs.